Welcome to our dedicated page for Sol Gel Tech news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Tech stock.
Sol-Gel Technologies Ltd. reports clinical, regulatory and commercial developments for a dermatology business focused on topical drug products for skin diseases. Company updates center on SGT-610, patidegib gel 2%, for the prevention of new basal cell carcinomas in Gorlin syndrome, and SGT-210, erlotinib ointment 5%, which has been evaluated in rare skin keratoderma indications including Darier disease.
News also covers TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea, including product approvals and territorial licensing or commercialization arrangements. Financial releases discuss research and development spending, revenue tied to partnerships and approved products, cash resources, shareholder voting matters, and capital-structure actions such as the company's reverse share split.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will release its first quarter 2020 financial results and operational highlights on May 14, 2020, at 7:05 AM ET. The company specializes in developing branded and generic topical drugs for skin diseases, utilizing proprietary microencapsulation technology for products such as Twyneo for acne and Epsolay for rosacea. Sol-Gel's pipeline includes early-stage treatments like SGT-210 for keratoderma and preclinical assets tapinarof and roflumilast.